Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results.
Cemiplimab plus chemotherapy continues showing lasting survival benefits for advanced lung cancer patients five years after initial treatment.
This PubMed record examines Cemiplimab plus chemotherapy versus chemotherapy in non-small-cell lung cancer with PD-L1 ≥1%: 5-year update of EMPOWER-Lung 3 Part 2 results. It reports CONCLUSIONS: First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.
What the study was
- Study design
- Phase 3 randomized controlled trial
- Population
- Human participants
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- ESMO open
Why it surfaced
Phase 3 randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.